Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis.
By T. Karamitsos, S. Piechnik, S. Banypersad, M. Fontana, N. Ntusi, V. Ferreira, C. Whelan, S. Myerson, M. Robson, P. Hawkins and 2 more. JACC Cardiovascular Imaging, 2013
645 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Molecular Biology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/c440a4489aeffa20e1744854d1e7ad9ef703e353
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement (2013, background): “When combined in a clinical scan protocol, early evidence suggests that native T1 mapping can reveal pathology such as area at risk in acute coronary syndromes [2,8,9,17], hitherto unsuspected pathologies (global myocarditis without LGE) and preclinical disease or unsuspected cardiac involvement (ir”
- T1-mapping in the heart: accuracy and precision (2014, background): “Elevated native T1 has also been reported in a number of diseases with cardiac involvement: myocarditis [24], amyloidosis [25], lupus [26], system capillary leakage syndrome [17], and decreases in native T1 have been associated with Anderson Fabry disease [27], and high iron content [28,29].”